



Advertisement

(-) U.S. markets close in 1 hour 16 minutes

| | | | | | |
|---|--|--|--|--|--|
| S&P 500 4,063.66 -68.27 (-1.65%) | Dow 30 32,457.80 -519.41 (-1.58%) | Nasdaq 12,207.74 -126.90 (-1.03%) | Russell 2000 1,843.02 -21.08 (-1.13%) | Crude Oil 105.35 +0.66 (+0.63%) | Gold 1,863.90 -47.80 (-2.50%) |
|---|--|--|--|--|--|

NIRV.CN 0.00%
newsfile

Nirvana Announces First Production of Psilocybin and Psilocin

Newsfile Corp.

April 21, 2022 · 3 min read

In this article:

NIRV.CN ☆
0.00%

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - Nirvana Life Sciences Inc. (**CSE: NIRV**) ("Nirvana" or the "Company") is pleased to announce that its supply agreement with Symeres B.V. has produced its first 20 grams of Psilocybin and 20 grams of Psilocin. These materials will support the Company's ongoing research and development projects.

Dr. Sazzad Hossain, Chief Scientific Officer of Nirvana commented, "We are very pleased to have these materials available as we enter the next phase of research and development." "Symeres has the capacity to produce and supply many of the compounds that are essential to our research".

About Symeres

Symeres is one of the largest European small molecule CRO & CDMOs, providing R&D services and manufacturing to major pharmaceutical and biotechnology companies around the globe. Its highly specialized services include integrated small molecule optimization efforts, complex synthetic chemistry,

Advertisement



Quote Lookup

Related Quotes

| Symbol | Last Price | Change | % Change |
|----------------------------|------------|--------|----------|
| NIRV.CN | 0.5700 | 0.0000 | 0.00% |
| Nirvana Life Sciences Inc. | | | |

Recently Viewed >

| Symbol | Last Price | Change | % Change |
|--------------|------------|---------|----------|
| EHVVF | 0.0100 | +0.0003 | +3.09% |
| EHAVE, Inc. | | | |

TRENDING

- UPDATE 3-Deliveroo backs off plan to cut pay of UAE delivery riders after strike**
- Stocks Push Toward Lowest Level in Almost a Year: Markets Wrap**
- Indian grocery startup Zepto raises new funds at \$900 million valuation**
- UPDATE 1-Sanctions will not be lifted until Russia signs peace deal with Ukraine -Germany's Scholz**



NIRV.CN 0.00%

Nirvana Life Sciences Inc. (NASDAQ: NIRV) is an innovator in the emerging Psychedelics space. Its business model combines the development of novel formulations for drug development with the development of laboratory space to support ongoing development and manufacturing. At Nirvana, we believe that psilocibins derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities. For more information visit

<https://www.nirvanalifescience.com/>

For further information:

Bruce Clark CEO


info@nirvanalifescience.com

Phone: 604-401-8100

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By

Uncover
the entertainment
industry's top 3
growth companies







...occur, which may cause the company's actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

NIRV.CN 0.00%

To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/121164>

Advertisement



RECOMMENDED STORIES



Motley Fool

Why Novavax Stock Is Soaring Today

What happened Shares of Novavax (NASDAQ: NVAX) were soaring 12.9% as of 11:24 a.m. ET on Monday. The gain continues the momentum that started on Friday after the Food and Drug Administration (FDA) announced plans...

3h ago

American City Business Journals

FDA orders stop to Vertex diabetes study

The U.S. Food and Drug Administration has hit Vertex Pharmaceuticals Inc. with a clinical hold, ordering a temporary stop to an early-stage study of a Type 1 diabetes drug.

Advertisement





Motley Fool

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

In fact, Narasimhan has proven to be a deal maker. Here is a sampling of what Novartis has bought since he took over as CEO in February 2018. Avexis, and what would become gene therapy Zolgensma, for \$8.7 billion i...

4h ago



Bloomberg

Pfizer Falls as Covid Pill Fails in Preventive Therapy Trial

(Bloomberg) -- Pfizer Inc. slumped after Paxlovid, its pill for treating Covid-19, failed to show benefit as a preventive therapy in a trial. Most Read from BloombergBiggest Treasury Buyer Outside U.S. Quietly Selling BillionsEnd...

5h ago



MarketWatch

Pfizer says Paxlovid doesn't work as a post-exposure prophylactic

Taking Pfizer Inc.'s COVID-19 pill Paxlovid failed to reduce the risk of spreading the virus to household contacts, the company said Friday. The drug maker had been testing Paxlovid as a post-exposure prophylactic in...

7h ago



Ad • Tomorrow Investor

This Rare Earth Mineral Is Transforming EVs

A major discovery out of Texas is replacing decades-old lithium-ion batteries with ones that are 5X more powerful, and last 5X longer.



TheStreet.com

Moderna Seeks Emergency Authorization for Under-6 Covid Vaccine

Children ages 6 months to under 6 years may soon have access to a Covid-19 vaccine that has been submitted to the FDA for emergency use authorization.

20h ago



Reuters

Moderna says its vaccine for ages under 6 will be ready for U.S. review in June

Moderna Inc's chief medical officer said on Sunday the company's vaccine for children under 6 years old will be ready for review by a Food and Drug Administration panel when it meets in June. Moderna sought emergency...

1d ago



Reuters

U.S. FDA declines to approve two more China-tested drugs

This is the second time the U.S. regulator has declined to approve a drug that was tested mainly in China. In March, it declined to approve Eli Lilly and partner Innovent Biologics Inc's lung cancer drug that had been...

8h ago


Ad • Cover Direct

Canadians Aged 30 - 65 Can Apply For This Benefit

Canadian residents aged 18 - 65 can apply for +\$300,000 benefits



Warren Buffett's right-hand man says the 'unraveling' of the trading platform after last... 22h ago




WWD To Succeed, ESG Practices Must Take a 'Management Approach' The report was done in partnership with Accenture, the Responsible Business Coalition, Fashion Makes Changes and WWD.

7h ago



Reuters Russia swerves to avoid default: what is next? Russia may have averted default as it announced it had made several overdue payments in dollars on its overseas bonds, shifting the market's focus to upcoming payments and whether it would stave off a historic...

14h ago



Ad • Altimetry BlackRock CEO Predicts Next Wave of Market Winners CEO of BlackRock says next 1,000 "Unicorns" (firms that get to \$1 billion+) will come from this sector you've probably never heard of.



Benzinga Lordstown, Foxconn Postponed Ohio Factory Sale Deadline Lordstown Motors Corp (NASDAQ: RIDE) agreed to push back the deadline to sell its Ohio factory to Hon Hai Precision Industry Co Ltd (OTC: HNHPF), operating as Foxconn, Bloomberg reports. The struggling EV startup need...

5h ago



Barrons.com Big Tech Can't Easily Fix the Stock Market's Woes This Time There wasn't much to celebrate in Big Tech earnings, but there was plenty to learn about the state of the world and the economy.

17h ago



Barrons.com Giant Pension Bought Tesla, Pfizer, and Starbucks Stock. It Sold Nike. STRS Ohio increased investments in EV maker Tesla, vaccine giant Pfizer, and cafe chain Starbucks, and cut holdings in apparel maker Nike in the first quarter.

1d ago



Ad • Red Gobo | Search Ads Here's How Much Toronto Maids Charge to Clean a House Getting A Maid May Be Cheaper Than You Think. Search Here.



India Accuses Xiaomi of Forex Violations in Latest
(Bloomberg) -- India accused Xiaomi Corp. of breaching the country's foreign-exchange la...
17h ago



MarketWatch
Farewell TINA? Why stock-market investors can't afford to ignore rising real yields.
Rising inflation-adjusted yields in the U.S. are undermining the long-running trade in which investors have favored stocks over other asset classes.
4h ago



Ad • Simply Urbans
Their Age Gap Makes Us Question Everything
They say age is just a number, but there is no missing these huge age gaps in these celebrity couples




Yahoo Finance
During COVID, shareholder wealth soared while workers were left behind: Brookings
The COVID-19 pandemic saw lower income populations around the world disproportionately affected in terms of financial impact while the amount of household wealth owned by the ultra-rich grew significantly. In a simila...
5h ago



MarketWatch
Tesla stock extends selloff, after biggest monthly drop in more than 2 years
Shares of Tesla Inc. slumped 1.2% in premarket trading Monday, adding to their worst monthly performance in more than two years, after China-based electric vehicle makers reported delivery declines. The electric...
6h ago



Investor's Business Daily
Chipmaker Onsemi Smashes First-Quarter Targets, Guides Higher
Chipmaker Onsemi smashed Wall Street's targets for the first quarter and guided higher for the current period.
36m ago





NIRV.CN 0.00%